Spondyloarthritis & psoriatic arthritis
Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target
An erratum to this article was published (Rheumatology (Oxford), 4 Jan 2024 ↗)
Authors' conclusion
This study shows that physicians do not always strictly apply treat-to-target in case of residual disease activity in axSpA. Usually, they accept low disease activity as satisfactory.
Study context
- Population
- Patients with a clinical diagnosis of axial spondyloarthritis (axSpA) ≥6 months
- Participants
- 249 patients
- Outcome
- Residual disease activity according to physician's opinion, patient's opinion and composite indices compared with subsequent treatment decisions
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- Remission according to the physician
- 115/249 (46%)
- Of those in physician-rated remission, remission according to BASDAI
- 37% (n = 43)
- Treatment left unchanged in patients with residual disease activity per physician and BASDAI >3.5
- 51/83 (60%)
- Unchanged because of low disease activity as rated by physician
- n = 15 (29%)
- Unchanged because of low disease activity with non-inflammatory complaints or comorbidities
- n = 11 (25%)
Observational data: associations, not effects.
Original publication
Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target. Rheumatology (Oxford). Published 6 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →